Education
About Us
Working with TipRanks
Follow Us
Pliant Therapeutics (PLRX)
NASDAQ:PLRX
Total Valuation
Pliant Therapeutics has a market cap or net worth of $87.17M. The enterprise value is $336.49M.
Market Cap$87.17M
Enterprise Value$336.49M
Share Statistics
Pliant Therapeutics has 61.39M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding61.39M
Owned by Insiders4.40%
Owned by Instutions0.50%
Financial Efficiency
Pliant Therapeutics’s return on equity (ROE) is -0.69 and return on invested capital (ROIC) is -62.60%.
Return on Equity (ROE)-69.16%
Return on Assets (ROA)-52.98%
Return on Invested Capital (ROIC)-62.60%
Return on Capital Employed (ROCE)-62.78%
Revenue Per Employee$0
Profits Per Employee-$1,229,847.953
Employee Count171
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Pliant Therapeutics is -3.79. Pliant Therapeutics’s PEG ratio is -0.14.
PE Ratio-3.79
PS Ratio0.00
PB Ratio2.62
Price to Fair Value2.62
Price to FCF-5.00
Price to Operating Cash Flow-5.13
PEG Ratio-0.14
Income Statement
In the last 12 months, Pliant Therapeutics had revenue of $0.00 and earned -$210.30M in profits. Earnings per share was -$6.12.
Revenue$0.00
Gross Profit-$1.14M
Operating Income-$228.37M
Pretax Income-$210.30M
Net Income-$210.30M
EBITDA-205.16M
Earnings Per Share (EPS)-6.12
Cash Flow
In the last 12 months, operating cash flow was -$155.50M and capital expenditures -$3.85M, giving a free cash flow of -$159.35M billion.
Operating Cash Flow-$155.50M
Free Cash Flow-$159.35M
Free Cash Flow per Share-$2.60
Dividends & Yields
Pliant Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-19.99%
Earnings Yield-26.38%
Stock Price Statistics
Beta1.24
52-Week Price Change-88.99%
50-Day Moving Average2.86
200-Day Moving Average10.37
Relative Strength Index (RSI)35.14
Average Volume (3m)2.13M
Important Dates
Pliant Therapeutics upcoming earnings date is May 12, 2025, After Close.
Last Earnings DateMar 3, 2025
Next Earnings DateMay 12, 2025
Ex-Dividend Date―
Financial Position
Pliant Therapeutics as a current ratio of 10.91, with Debt / Equity ratio of 0.10
Current Ratio10.91
Quick Ratio10.91
Debt to Market Cap0.04
Net Debt to EBITDA0.18
Interest Coverage Ratio-10.83
Taxes
In the past 12 months, Pliant Therapeutics has paid $469.72K in taxes.
Income Tax$469.72K
Effective Tax Rate0.00%
Enterprise Valuation
Pliant Therapeutics EV to EBITDA ratio is -3.31, with an EV/FCF ratio of -4.74.
EV to Sales0.00
EV to EBITDA-3.31
EV to Free Cash Flow-4.74
EV to Operating Cash Flow-4.86
Balance Sheet
Pliant Therapeutics has $355.72M in cash and marketable securities with $60.19M in debt, giving a net cash position of -$295.53M billion.
Cash & Marketable Securities$355.72M
Total Debt$60.19M
Net Cash-$295.53M
Net Cash Per Share-$4.81
Tangible Book Value Per Share$5.02
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Pliant Therapeutics is $5.25, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$5.25
Price Target Upside259.59%
Analyst ConsensusHold
Analyst Count13
Revenue Growth Forecast-100.00%
EPS Growth Forecast-26.44%